ISID Executive Committee
2004–2006

Francisco Antunes
Portugal
Keryn Christiansen (President)
Australia
Raul Istoriz
Venezuela
Dennis L. Kasper (Past-President)
USA
Keith Klugman
USA
Carl-Erik Nord (Treasurer)
Sweden
Heikki Peltola
Finland
Didier Raoult
France
Jingoro Shimada (Secretary)
Japan
Richard Wenzel (President-Elect)
USA
Norman Stein
(Executive Director) USA
Timothy Brewer
(Program Director) CANADA
Amy Galblum
(Program Coordinator) USA

ISID NEWS
1330 Beacon Street, Suite 228
Brookline, MA 02446 USA
Telephone: (617) 277-0551
Fax: (617) 278-9113
E-mail: info@isid.org
http://www.isid.org

Abstract Deadline for the 12th ICID
Extended to March 1, 2006

A Letter from the President

Dear Colleagues,

It is with great pleasure that I invite you to attend the 12th International Congress on Infectious Diseases to be held in Lisbon in June 2006.

With many meetings both large and small during any one year we must ask, as a Society, what is it that is important to our membership? What is it that distinguishes one meeting from another? Why will the 12th ICID be the meeting you will want to attend?

Scientific conferences provide an important opportunity for the sharing of experience and the acquisition of new information. They allow new friendships to be forged, those already established to be renewed, and collaborative endeavours to be kindled.

What sets the ISID apart is its membership from more than 100 countries, its focus on both low- and high-resource countries and their problems, and its provision of the opportunities to see the results of its various scientific and educational programs. You will all undoubtedly be familiar with ProMED-mail. This ISID program has made a major contribution to outbreak reporting—it has led the way with information on outbreaks such as SARS and avian influenza. Likewise the program of the conference will lead the way in bringing world-renown speakers to address issues of emerging infectious diseases and advances in diagnostic techniques as well as practical sessions on therapeutic problems and their solutions, infection control issues, and the ever-increasing problem of antimicrobial resistance. The usual format of the congress—plenary sessions, symposia, ‘meet-the-professor’ and poster presentations—will be supplemented with workshops to enhance the exchange of experience and knowledge. ISID is a dynamic society with a commitment to serve its members by providing an exciting atmosphere for learning and sharing of information.

It is appropriate that the 12th ICID will be held in Lisbon, a beautiful and dynamic city. Set on many hills, it is a multicolored city with bright yellow buildings, happy, friendly people, and a relaxed and interesting culture. The sun will be warm, the food will be good, and the company superb. Infectious disease practitioners, whether they are clinicians, scientists, researchers, or other health care practitioners, are attracted to the discipline for many reasons and recognize that it provides a lifetime of challenges. Come and share these challenges with your colleagues. Come and join us in Lisbon. We look forward to your contributions and to your fellowship.

Keryn Christiansen, M.D.
President, International Society for Infectious Diseases

The 12th ICID Preliminary Program is available online at http://www.isid.org/12th_icid/
The 12th ICID in Lisbon

The organizers are pleased to announce that our list of plenary speakers now includes Nobel Laureate, Dr. Barry J. Marshall, recipient of the 2005 Nobel Prize in Physiology or Medicine. Dr. Marshall is an Australian physician and Professor of Clinical Microbiology at the University of Western Australia. In 1982, he and colleague, Dr. Robin Warren, performed the initial culture of *H. pylori* and developed their hypothesis related to the bacterial cause of peptic ulcer and gastric cancer.

Marshall and Warren discovered that a bacterium, *Helicobacter pylori*, causes of one of the most common and important diseases of mankind, peptic ulcer disease. This disease is now cured by a simple course of antibiotics.

Their work has now been acknowledged as the most significant discovery in the history of gastroenterology and is compared to the development of the polio vaccine and the eradication of smallpox.

Professor Marshall continues research related to *H. pylori* and runs a molecular biology lab at UWA. His address is titled, “From Social to Infectious Disease, Ulcers and the Discovery of *Helicobacter pylori*."

Dr. Marshall, along with the five other exciting plenaries highlighted in previous issues of the ISID NEWS, will provide participants with state-of-the-art updates on a topics of special interest.

---

**Barry MARSHALL, Australia**
From Social to Infectious Disease, Ulcers and the Discovery of *Helicobacter pylori*

**Edward FEIL, United Kingdom**
Bacterial Microevolution: Relevance to the Clinician

**Antoni TORRES, Spain**
Severe Community-acquired Pneumonia—A Genetic Predisposition?

**Adel MAHMOUD, United States**
A New Era for Immunization in Public Health

**Bernhard SCHWARTLÄNDER, Switzerland**
The Impact of the Global Fund to Fight AIDS, Tuberculosis and Malaria after Five Years

**Bonnie BASSLER, United States**
Bacterial Crosstalk: Implications for Pathogenesis And Treatment

---

**ISID would like to acknowledge the following**

**COLLABORATING AND COOPERATING ORGANIZATIONS**

12th International Congress on Infectious Diseases • Lisbon, Portugal • June 15–18, 2006

**Collaborating Organizations:**
Portuguese Society of Infectious Diseases (SPDI)
Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC)

**Cooperating Organizations:**
Association of Medical Microbiologists, United Kingdom (AMM)
Brazilian Society of Infectious Diseases (SBI)
Croatian Society of Infectious Diseases (CSID)
Danish Society for Clinical Microbiology (DSKM)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Finnish Society for Clinical Microbiology
French Infectious Diseases Society (SPILF)
German Society of Infectious Diseases (DGI)
Hellenic Society for Infectious Diseases
Norwegian Society of Medical Microbiology (NFMM)
Pan American Association of Infectious Diseases (API)
Swiss Society for Infectious Diseases (SSI)
Turkish Microbiological Society (TMC)
World Organization for Animal Health (OIE)

---

**ISID would like to acknowledge the following**

12th International Congress on Infectious Diseases

**PREMIER SPONSORS**

Chiron Vaccines
GlaxoSmithKline
MSD and SPMSD
Wyeth
Confirmed Speakers as of February 17, 2006

ALARCON, Aristides (Spain)
AMARAL, Leonard (Portugal)
ARIZA, Javier (Spain)
ASHLEY, Elizabeth (Thailand)
AYLWARD, Bruce (Switzerland)
BASSLER, Bonnie (USA)
BEN JEBARA, Karim (France)
BRUNETTI, Enrico (Italy)
CAHN, Pedro (Argentina)
CAPUA, Ilaria (Italy)
CERCENADO, Emilia (Spain)
CHOKEPHAIBULKIT, Kulkanya (Thailand)
COHEN, Jon (United Kingdom)
CRUBEZY, Eric (France)
DABIS, Francois (France)
DAGAN, Ron (Israel)
DE LENCASTRE, Herminia (Portugal)
DRANCOURT, Michel (France)
DUSE, Adriano (South Africa)
EUROS, Jose (Spain)
EREMIN, Sergei (Russia)
ETIENNE, Jerome (France)
FARRELL, David (United Kingdom)
FEDSON, David (France)
FEIL, Edward (United Kingdom)
FINCH, Roger (United Kingdom)
FLAHAUT, Antoine (France)
GAVALDA, Joan (Spain)
GIAQUINTO, Carlo (Italy)
GOFFREY-FAUSSETT, Peter (United Kingdom)
GOLENBOCK, Douglas (USA)
GOTUZZO, Eduardo (Peru)
GRAYBILL, John (USA)
HEYMANN, Sally (USA)
HILL, Adrian (United Kingdom)
HIMMICH, Hakima (Morocco)
HIRSH, Aaron (USA)
IBRAHIM, Salah (Sudan)
JOHNSON, Bob (United Kingdom)
JOHNSTON, Margaret (USA)
KLUGMAN, Keith (USA)
KNOBEL, Hernando (Spain)
LEVIN, Byron (USA)
LILJESTROM, Peter (Sweden)
LINDE, Hans-Joerg (Germany)
LOW, Don (Canada)
LUCET, Jean-Christophe (France)
LUZURIAGA, Katherine (USA)

12th International Congress on Infectious Diseases • Symposia

June 15–18, 2006 • Lisbon, Portugal

The following symposia are being organized ~ Updated February 3, 2006.

Advances in Microbiology: Science Improving Care
- Using the Clinical Laboratory to Limit Hospital Antibiotic Resistance
- Anti-Fungal I Resistance Testing: When is it Needed to Improve Care?
- DNA Chips in Clinical Microbiology
- Comparative Genomics: Is it of Any Clinical Use?

Pediatric HIV: Hope for a Better Future
- HIV Vaccines, Issues for Children and Adolescents
- Protecting Mothers and Children: HIV MTCT in Low-resource Settings
- Treatment of Pediatric HIV: State of the Art in 2006
- Optimizing Pediatric HIV treatment in Low-resource Settings

Animals and Insects: Old and New Diseases in the Mediterranean Region
- Rabbits, Hares and People: Tularemia on the Iberian Peninsula
- Brucellosis
- Q Fever
- Update on Echinococcosis

Early Detection and Rapid Response to Animal Diseases and Zoonoses
- Avian Influenza: An Emerging Zoonotic Pathogen
- OIE System for Notification and Surveillance of Animal Diseases and Zoonoses
- Contribution of Other International and Non Governmental Organisations Involved
- Investigating the Role of Animals in the Origin of Zoonotic Emergencies
- Early Detection and Rapid Response: An International Public Good

The Need for New Antimicrobial Agents and Vaccines
- An Emerging Health Crisis in USA
- The European Response to the Technology Gap
- Promotion of Anti-Infective Development in Developing Countries
- New Public Health Threats

HIV Challenges in High and Low Resources Settings
- Preventing HIV: Options Beyond Vaccines
- Expanding ARV Therapy in Limited Resource Settings
- Managing ARV Therapy: When to Start, When to Change
- New Treatment Options on the Horizon

Pediatric Respiratory Tract Infections: Old problems, New Insights
- Infections and Asthma: Understanding the Relationships
- Tuberculosis: Recognition and Management in Children With and Without HIV
- Pertussis: Increasing Old Problem
- Measles: The Sudanese Experience
- Pediatric Influenza

New Developments in Institutional MRSA Control
- Worldwide MRSA Spread: The Bridge Between Molecular Biology and Healthcare
- Evidence: What Works, What does not Work for MRSA Control?
- Successful Control of Endemic MRSA: Is it Possible?
- Rapid Screening for MRSA: Myth or Reality?

Antibiotic-Resistant S. pneumoniae Antibiotic Restriction and Pneumococcal Vaccines
- Do PD/PK Parameters Predict Emerging Resistance?
- New Antibiotics and New Antibiotic-resistance Mechanisms in pneumococci
- What Have We Learned from Trends in Antibiotic Resistance After Introduction of PCVs?
- Do Interventions in Antibiotic Use Influence Antibiotic-resistant S. pneumoniae?

Septic Shock
- Innate Immunity: Friend or Foe?
- Are All Hosts Equal? Do Genetics Matter?
- Antibiotic Choice in Sepsis: A Forgotten Art
- Steroids Good or Bad—A Critical Appraisal

Modern Identification of the Outbreaks of the Past
- Plague and Black Death
- Spanish Influenza
- Mycobacterium Disease at the Origins of Urban Life in Egypt
- Human Louse Infestations: Past and Present
- Pre-Columbian Syphilis

Pandemic Influenza: Are We Ready Yet?
- The Molecular Virology of Influenza Vaccines and Its Implications for the Next Pandemic
- Pandemic Influenza Preparedness at the National and International Level
- Prevention and Control of the Next Pandemic with Vaccines and Antivirals: Prospects for an Equitable Global Supply
- The Political Dimensions of the Next Influenza Pandemic: A Threat to Global Health Security

continued on next page
12th International Congress on Infectious Diseases • Symposia

June 15–18, 2006 • Lisbon, Portugal

The following symposia are being organized ~ Updated February 3, 2006.

New Directions in Malaria Treatment
• How PD/PK Characteristics and Resistance Affect Treatment Strategies
• Assessing Treatment Efficacy in Vivo: What Should We Follow?
• Treating Resistant Malaria in Pregnancy
• New Antimalarial Agents and New Therapeutic Combinations

Preventing the Big Three: Vaccines for Malaria, TB, and HIV
• Cell-mediated Immunity: Challenges for Developing Effective Vaccines
• Update on Malaria Vaccines: In the Field and the Laboratory
• Tuberculosis Vaccines: Ready for Prime Time?
• The Status and Future Directions of HIV Vaccine Development

Tuberculosis and HIV Infection
• Treatment of Tuberculosis in HIV-infected Patients
• Treatment of Latent Tuberculosis Infection in HIV-infected Patients
• Strategies to Improve Patient Adherence to Tuberculosis Treatment
• Infection Control and Treatment of Latent Infection in Patients with Multidrug-resistant Tuberculosis

Hepatitis C in Patients With HIV
• Epidemiology and Natural History of HIV-HCV Coinfection
• HCV and Risk of Hepatotoxicity with HAART
• Therapeutic regimens for hepatitis C in HIV-infected patients
• Liver Transplantation in HIV-infected Patients

Update on Pneumococcal Vaccines
• Update on Conjugate Pneumococcal Vaccine Effect on Invasive Disease, Pneumonia and Herd Immunity.
• The Replacement Phenomenon in PCV—What are the Implications?
• Pneumococcal Protein-based Vaccines: The Next-Generation Pneumococcal Vaccines?
• Global Pediatric Pneumococcal Vaccination Implementation: Where Are We in 2006?

Challenges in Infection Control in Low-Resource Countries
• Quality Improvement in Infection Control in Resource Limited Setting
• Surveillance for the Detection and Control of Multiple Drug Resistant Nosocomial Pathogens in the Middle East
• Establishing Effective Control Programs for Surgical Site Infections
• Dealing with Formidable and Novel Pathogens in Minimally-resourced Settings

Optimizing Care for Invasive Fungal Infections
• Diagnosing Fungal Infections: What Test Strategies Improve Outcomes?
• Fungal Infections in the ICU: When and What Empiric Therapy?
• Pro: Is Combination Anti-Fungal Therapy the New Standard for Invasive Fungal Infections
• Con: Is Combination Anti-Fungal Therapy the New Standard for Invasive Fungal Infections

Vaccines for Children: New Strategies
• Present and Future of Rotavirus Vaccines
• Hepatitis A: Experiences with Universal Immunization
• Polio: Defining the Optimal Vaccine Strategy
• Vaccination for Premature Infants: What Vaccines When?

Tuberculosis: Past, Present and Future
• Genetic Evolution of Tuberculosis: Co-Travelers in Global Migration
• Diagnosing Tuberculosis: Options for High and Low Resource Areas
• Tuberculosis Drug Development: Where Are We in 2006?
• Tuberculosis Control Beyond DOTS: What Do We Know?

The Role of Women in Infectious Diseases
• The Current Role of Women in Families in the Global Prevention and Control of Infections
• Women as High-Risk Victims of Infection
• Women as Leaders in the Effort to Control Infections
• The Relation Between Women’s Rights and Infectious Diseases

Beyond Institutions: MRSA in the Community
• Clonal Epidemiology Worldwide
• Prevalence and Risk Factors
• Treatment Options for Community-acquired Staphylococcal Infections: End of Beta-lactam Era?
• Control Strategies

continued on next page

12th ICID Satellite Symposia

Protecting Health—Time and Time Again ‘A Symposium on the New Generation of GSK Vaccines’
—Sponsored by Glaxo SmithKline

Added Value of Adjuvant Systems in Flu Vaccines for Pandemic Preparedness and Beyond
—Sponsored by Chiron Vaccines

Confirmed Speakers

MADHI, Shabir (South Africa)
MAHMOUD, Adel (USA)
MANSINGH, Kamal (Portugal)
MANUGUERRA, Jean-Claude (France)
MARSHALL, Barry (Australia)
MATRICARDI, Paolo (Germany)
MAYER, Kenneth (USA)
MCINTOSH, Ken (USA)
MEHTAR, Shaheen (South Africa)
MEMISH, Ziad (Saudi Arabia)
MERTSOLA, Jussi (Finland)
MIRA, Jean-Paul (France)
MIRO, Jose Maria (Spain)
MITCHELL, Tim (Scotland, UK)
MORENO, Santiago (Spain)
MORETTI, Maria Luiza (Brazil)
MULLIGAN, Connie (USA)
MUMCUOGLU, Kosta (Israel)
MUTABINGWA, Theoneste (Bangladesh)
O’BRIEN, Kate (USA)
O’RYAN, Miguel (Chile)
ODIO, Carla (Costa Rica)
PINEDA, Juan Antonio (Spain)
RAOULT, Didier (France)
REED, Steve (USA)
ROSSI, Flavia (Brazil)
SARMENTO E CASTRO, Rui (Portugal)
SCHRENZEL, Jacques (Switzerland)
SCHWARTLANDER, Bernhard (Switzerland)
SHIBL, Atif (Saudi Arabia)
SHIMSHONY, Arnon (Israel)
SPRUNG, Charles (Israel)
STOHR, Klaus (Switzerland)
STONE, Sheldon (United Kingdom)
TAUBENBERGER, Jeffery (USA)
TEMMERMANN, Marleen (Belgium)
TORRES, Antoni (Spain)
TURNIDGE, John (Australia)
VALADAS, Emilia (Portugal)
VALLAT, Bernard (France)
VAN ELDERE, Johan (Belgium)
WATSON, Peter (Canada)
WEIL-OUJIVER, Catherine (France)
WELDINGH, Karin (Denmark)
WHITE, Nicholas (Thailand)
WOLF, Michel (France)
12th International Congress on Infectious Diseases • Symposia

June 15–18, 2006 • Lisbon, Portugal

The following symposia are being organized ~ Updated February 3, 2006.

Protection Against Cervical Cancer and Earlier Lesions: Short and Long-Term Impact of a Quadrivalent HPV Vaccine

- Cervical Cancer and Earlier HPV Related Lesions in My Gynecology Clinic and in the World
- An Overview of the Clinical Development and Results of a Quadrivalent HPV Vaccine
- Immune Response and Long-Term Protection with Quadrivalent HPV Vaccine: What We Know Now and What We Will Know Later
- Audience Response—Programmatic Issues for Cervical Cancer and HPV Vaccination:
  - Age of Vaccination
  - Universal Vaccination and Genders
  - Parent and Vaccinees’ Acceptability
  - Complementary to Screening

Prevention of Herpes Zoster and Its Painful and Debilitating Complications

- Burden of Herpes Zoster Disease: Epidemiology and GP’s Perception
- Herpes Zoster: A Severe Disease
- A Vaccine to Prevent HZ and PHN: An Answer to An Unmet Need

Evaluation of Current Polysaccharide Vaccines

- Epidemiology of Pneumococcal Disease and Efficacy of Polysaccharide Vaccines in Adults
- Institutional Protocols and Adult Vaccination
- Outcomes of Vaccination in Adults With Polysaccharide Vaccine—Australian Experience

Meet the Expert

- The Need for Vaccination—Preventing Herpes Zoster
- Why a Vaccine? Why to Vaccinate Against HZ?
  (Next Steps SPS): Myron Levin

Outbreaks and Natural Disasters

ISID Small Grants Program • Fall 2005 Awardees

Paul Bessong
Department of Microbiology
University of Venda
South Africa

Project: Drug Resistance in HIV-1 Subtype C

Luis Bribea de Castro
Department of Biochemistry
CINVESTA
México

Project: Structural Studies of the EhCP112 Cysteine Protease from Entamoeba histolytica

Azure Tariro Makadzange
University of Zimbabwe
School of Health Sciences
Zimbabwe

Project: The Appropriate Management of Cryptococcal Meningitis in Sub-Saharan Africa: A Study of Immediate vs. Deferred Anti-Retroviral Therapy in the Treatment of Cryptococcal Meningitis with Long-Term Follow-up to Determine When it is Safe to Discontinue Secondary Prophylaxis Against Cryptococcal Meningitis

The Small Grants Program is designed to fund pilot research projects by young investigators in developing countries. The goal is to support and foster the professional development of young individuals in the field of infectious diseases research by helping them to acquire additional skills and data to apply for other grants. Areas of interest include, but are not limited to investigations of the epidemiology, pathophysiology, diagnosis or treatment of infectious diseases, the epidemiology and control of hospital-acquired infections, and modeling of cost effective interventions.
A Letter from the Editor

Beginning in February 2006, ProMED-mail will initiate a paid Premium Subscription service. While all of our reports will continue to be available free of charge, we will make additional services available to our paid subscribers. These new features will include our Daily and Weekly Updates (which have been available on a free trial basis for the past year). In the future, paid subscribers will also have access to a mapping feature that will use GIS to locate ProMED reports and enhanced access to our archives.

Since 1994, we have gathered and delivered news on emerging diseases accompanied by commentaries from our expert moderators. Beyond reporting on human diseases like SARS, dengue, West Nile virus, and biological weapon threats like anthrax, we report the latest news on animal and plant diseases with the potential to affect human health. One need look no further than BSE and avian influenza to understand the direct connection between animal and human health.

ProMED-mail is a unique resource that has become a valuable tool for thousands of readers, medical practitioners, public health workers, researchers, and others around the globe. Our reports are posted around the clock, so you get the reliable information you need as it becomes available. ProMED-mail provides a valued forum in which anyone can report an outbreak or ask a question and through which anyone in need of assistance or answers can communicate with experts from around the world.

As an independent non-profit, non-governmental organization, we have always been committed to providing our information objectively and at no charge to our subscribers. The cost of operating ProMED-mail is considerable, however, and this new service will help support and ensure its future.

Sign up for a Premium Subscription

These will be available today 8 Feb 2006 at an introductory cost of 39 USD per year.

• Access ProMED-mail through our Daily and Weekly Updates, with clickable links directly to the posts that interest you
• Use the ProMED-mail GIS/mapping service when it comes online
• Support ProMED-mail

Please note that the Daily and Weekly Updates differ from the Digests in that they are simply lists of titles of posts with clickable live links to the actual articles. The advantage is that they take up less Inbox space than the Digests, and you don’t have to scroll down through lots of text to find the item that interests you.

Regular Members of the International Society for Infectious Diseases will receive premium services as a benefit of membership, so now is the time to sign up for membership in ISID (http://www.isid.org).

How to sign up for a Premium Subscription

Go to our website (http://www.promedmail.org) and click on the subscription link on the left side of the page. There, you will be able to select the services you wish (as well as unsubscribe from any you no longer require).

ProMED depends on our participants, not only for the reports sent us, but for our continued financial well-being.

Please sign up for a Premium Subscription today.
Editor

*International Journal of Infectious Diseases*

These *IJID* is the official publication of the International Society for Infectious Diseases. The Journal seeks to enhance understanding of the cultural and medical factors affecting infectious diseases throughout the world and provides insight into traditional and regional methods of infectious-disease management. The *IJID* communicates and disseminates information relevant to the epidemiology, clinical evaluation, diagnosis, treatment and control of infectious Diseases, with an emphasis on those diseases most prevalent in less-developed countries.

Contributions to *IJID* include reports of regional clinical and laboratory research, articles focusing on epidemiology and preventive medicine, clinical reports on local and regional issue of international interest, report of clinical trials, reviews and occasional case reports. The *IJID* is indexed in Medline.

- The post of Editor-in-Chief of the *IJID* will become vacant in July 2006.
- The appointment is for 3-5 years.
- The Journal requires an enthusiastic and creative specialist in the field to: maintain the Journal’s high publication standards, oversee the Journal’s peer review process, steer the Journal’s editorial development, ensure the Journal’s continuing success, and work closely with the Journal’s International Corresponding Editors

Previous editorial experience is desirable but not essential. A modest stipend is available to the successful candidate to cover editorial office expenses.

Any person who would be interested in being considered for the post is invited to submit.

*A letter of interest and C.V. to the Editorial Search Committee, attention:*

Norman Stein, International Society for Infectious Diseases • 1330 Beacon Street, Brookline, MA 02446 • USA
Phone: (617) 277-0551 • Fax: (617) 278-9113 • E-mail: Norman.Stein@isid.org

**Closing date for applications: 30th March 2006**

---

**Position Available**

**Program Director**

**International Society for Infectious Diseases**

The Program Director is responsible for overseeing all scientific, training, educational, and professional development programs for this non-profit professional organization with members in over 100 countries. Principal responsibilities include program development and management, supervision of personnel, and fund raising. This position requires a strong understanding of infectious diseases clinical practice and research, management and communications skills, the ability to work with individuals from diverse background around the world, and solid writing skills. Previous experience working internationally is helpful.

Minimum requirements: MD with training in infectious diseases. This part-time position is located in Boston and involves some travel. The compensation and benefits are competitive with academic institutions in the area.

For further information about the ISID and its programs please visit our website at http://www.isid.org/

**Interested applicants are encouraged to forward a letter of interest and CV to:**

ISID Search Committee • 1330 Beacon Street, Brookline, MA 02446 USA • info@isid.org